| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5882868 | Clinical Lymphoma Myeloma and Leukemia | 2016 | 15 Pages |
Abstract
With monitoring and prophylaxis, alemtuzumab 60 mg combined with CHOP showed activity in CD52+ PTL and achieved the highest drug levels.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Rena Buckstein, Graeme Fraser, Matthew Cheung, Vishal Kukreti, John Kuruvilla, Kevin Imrie, Eugenia Piliotis, Gregory Pond, Jolanta Windsor, Zeina Ghorab, Kevin Shuoprasad, Ruth Turner, Ralph M. Meyer, Kathy Pritchard, Scott Walker, Mark Levine,